Key takeaways
- Cagrilintide is a long-acting amylin analogue from Novo Nordisk; CagriSema is its fixed combination with semaglutide, the active ingredient of the prescription medicines Ozempic and Wegovy.
- ClinicalTrials.gov lists 23 phase 3 studies with cagrilintide, all sponsored by Novo Nordisk, which funded every trial on this page (18 Nov 2026).
- REDEFINE 1 and REDEFINE 2, published in NEJM in June 2025, enrolled 3,417 and 1,206 adults for 68 weeks; the heart-outcomes trial, REDEFINE 3, with 7,076 participants, has published only its design.
- Novo Nordisk said on 20 October 2026 that “CagriSema is not approved for use in the United States”; FDA says cagrilintide “cannot be used in compounding under federal law”.
- FDA warning letters dated December 2024 and March 2026 listed products sold online as “Cagrilintide”, labelled for research use, among unapproved new drugs.
01Cagrilintide at a glance
The short version, dated 18 November 2026.
| Question | Cagrilintide |
|---|---|
| What it is | A long-acting analogue of amylin, a hormone made by the pancreas. Novo Nordisk is developing it alone and combined with semaglutide. |
| Other names | CagriSema is the fixed combination of cagrilintide and semaglutide. Trial papers also write it as cagrilintide–semaglutide. |
| Developer | Novo Nordisk, which funded every trial on this page. |
| Evidence tier | T1, investigational: randomised, placebo-controlled trials of Novo Nordisk’s product, published from 2021 to 2026. |
| Phase 3 studies | ClinicalTrials.gov lists 23, all sponsored by Novo Nordisk: 10 completed, 6 active and not recruiting, 5 recruiting, 1 not yet recruiting and 1 withdrawn. |
| United States | Not approved. Novo Nordisk filed a New Drug Application for CagriSema in December 2025 and expects a decision in the fourth quarter of 2026. FDA says cagrilintide “cannot be used in compounding under federal law”. |
| European Union | No EU-wide authorisation: the EMA’s data on centrally authorised medicines (17 Nov 2026) lists no medicine containing cagrilintide. |
| Australia | Not named in the Poisons Standard October 2026 (text searched 18 Nov 2026), and not being named does not make it approved or permitted. We did not assess its group entries. |
02What are cagrilintide and CagriSema?
Cagrilintide is a long-acting analogue of amylin, a hormone made by the pancreas. Novo Nordisk developed it, and the trials on this page tested the company’s own product in adults with overweight or obesity, some of them with type 2 diabetes.
CagriSema is a fixed combination of cagrilintide with semaglutide. The two act on different receptors. Semaglutide is a GLP-1 receptor agonist and the active ingredient of the prescription medicines Ozempic, Wegovy and Rybelsus. Cagrilintide is not a GLP-1 drug: the REDEFINE 3 design paper describes it as an amylin receptor agonist. Novo Nordisk calls CagriSema an investigational fixed combination.
Cagrilintide has also been tested alone. Its phase 2 trial (The Lancet, 2021) compared five levels of cagrilintide with placebo and an active comparator for 26 weeks, with 100 to 102 adults without diabetes in each cagrilintide group. The primary endpoint was the percentage change in body weight. How we grade evidence like this: evidence grades.
03What did the REDEFINE phase 3 trials measure?
REDEFINE is Novo Nordisk’s phase 3 programme for CagriSema in overweight and obesity.
Each trial below was randomised and funded by Novo Nordisk. We list who took part and what each set out to measure, not efficacy figures for a drug that is not approved.
| Trial and paper | Who took part | Length | Primary endpoint |
|---|---|---|---|
| REDEFINE 1 · NEJM, online 22 Jun 2025 | 3,417 adults without diabetes, with a body-mass index (BMI) of 30 or more, or 27 or more with an obesity-related condition, randomised to CagriSema, semaglutide alone, cagrilintide alone or placebo | 68 weeks | Percentage change in body weight, and the proportion reaching a reduction of at least 5%, CagriSema against placebo |
| REDEFINE 2 · NEJM, online 22 Jun 2025 | 1,206 adults with type 2 diabetes and a BMI of 27 or more, in 12 countries, randomised 3 to 1 to CagriSema or placebo | 68 weeks | The same two endpoints |
| REDEFINE 3 · design paper, Am Heart J, online 6 Oct 2026 | 7,076 adults with established cardiovascular disease and a BMI of 25 or more, with or without type 2 diabetes, at 575 sites in 24 countries, randomised to CagriSema or placebo | Ongoing | Safety: whether CagriSema is no worse than placebo (non-inferior) on cardiovascular death, non-fatal heart attack or non-fatal stroke; efficacy: whether it is better than placebo (superior) on the same events plus artery-reopening procedures |
| REDEFINE 9 · Lancet Diabetes Endocrinol, online 14 Nov 2026 | 309 adults without diabetes, with a BMI of 30 or more, or 27 or more with an obesity-related condition, at 24 sites in five countries, randomised to two lower-strength versions of CagriSema or placebo (phase 3b) | 68 weeks | Percentage change in body weight, and the proportion reaching a reduction of at least 5% |
Adverse events. These describe Novo Nordisk’s product under trial conditions. In the phase 2 trial of cagrilintide alone, the most frequent adverse events were gastrointestinal, such as nausea, constipation and diarrhoea, and reactions at the administration site. In REDEFINE 1, gastrointestinal adverse events affected 79.6% of people given CagriSema and 39.9% given placebo; in REDEFINE 2, 72.5% and 34.4%. The authors describe most of them as transient and mild to moderate. In REDEFINE 9, adverse events were reported in 95% to 99% of people given CagriSema and 91% given placebo, mostly mild or moderate and gastrointestinal; no deaths were reported.
None of this describes material sold outside the trials, which has not been through them. How to read safety data like this: side effects, documented vs unknown.
04Is cagrilintide approved?
No. As of 18 November 2026, no medicine containing cagrilintide is approved in the US or the EU.
United States. Novo Nordisk announced on 18 December 2025 that it had submitted a New Drug Application to FDA for CagriSema, based on REDEFINE 1 and REDEFINE 2. A submission asks FDA to review the evidence; it is not an approval. On 20 October 2026 the company said a decision is expected in the fourth quarter of 2026, that “CagriSema is not approved for use in the United States” and that “Safety and efficacy are not established.” A search of Drugs@FDA on 18 November 2026 returned no product containing cagrilintide.
FDA’s page on unapproved GLP-1 drugs (content current 1 October 2026) says: “Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition.” US drug law and peptides: are peptides legal in the US?
European Union. In December 2025, Novo Nordisk said CagriSema “is not approved in the US or EU.” The EMA’s data on centrally authorised medicines, dated 17 November 2026, lists no medicine containing cagrilintide.
Australia. Cagrilintide is not named in the Poisons Standard October 2026, and not being named does not make it approved or permitted; we did not assess whether a group entry covers it. Australian rules on unapproved peptide products: are peptides legal in Australia?
05Why are products sold online as cagrilintide not the trial drug?
Every trial above tested Novo Nordisk’s product. Material sold online under the same name has not been through those trials, and FDA has acted on it.
FDA warning letters. On 10 December 2024, FDA wrote to an online seller that its “Cagrilintide” product, sold alongside products listed as semaglutide, retatrutide, tirzepatide and mazdutide, was among unapproved new drugs, despite labels reading “RESEARCH USE ONLY” and “INTENDED AS A RESEARCH CHEMICAL ONLY”. A second letter, dated 31 March 2026, listed another seller’s “Cagrilintide” among unapproved new drugs despite labelling for “laboratory research purposes only” and “not for human consumption, medical use or veterinary use”. In both letters FDA said evidence from the sellers’ websites established that the products were intended to be drugs for human use.
A lab report can show what one tested sample contained: its identity, amount and purity. It cannot turn that sample into the product Novo Nordisk tested, or into an approved medicine. How identity is checked: mass spectrometry explained. The same pattern, for another pipeline drug: retatrutide.
06What we don’t know
- Whether FDA will approve CagriSema, or when. Novo Nordisk expects a decision in the fourth quarter of 2026.
- What REDEFINE 3 will show for heart attack, stroke and cardiovascular death. The trial is listed as active, not recruiting, with primary completion expected in September 2027 (NCT05669755); only its design has been published.
- What phase 3 trials of cagrilintide on its own will report. Novo Nordisk has registered several, among them RENEW 1, 2 and 4; none has posted results, and we found no journal paper from them (ClinicalTrials.gov and PubMed, 18 Nov 2026).
- What any vial sold online contains. A lab report shows only what the tested sample held.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.